COACTIVATION OF D1 AND D2 DOPAMINE-RECEPTORS IS REQUIRED FOR LONG-TERM SYNAPTIC DEPRESSION IN THE STRIATUM
COACTIVATION OF D1 AND D2 DOPAMINE-RECEPTORS IS REQUIRED FOR LONG-TERM SYNAPTIC DEPRESSION IN THE STRIATUM
复制标题
DOI：
10.1016/0304-3940(92)90628-k
复制
发表时间：
1992-08-03
影响因子：
2.5
通讯作者：
BERNARDI, G
中科院分区：
文献类型：
--
作者：
CALABRESI, P;MAJ, R;BERNARDI, G
在大脑兴奋性通路的短暂高频刺激之后，突触传递的长期变化作为记忆的可能相关性而引起了人们的注意。在小脑中，并行纤维和攀爬纤维的同时激活导致突触传递的长期抑制（LTD），这可能是该结构中运动学习的细胞基质。我们在这里报告的第一次，高频刺激的皮质纹状体amatergic纤维在纹状体，另一个大脑结构强烈参与运动控制，也诱导LTD的突触传递。纹状体LTD的诱导可被D1多巴胺（DA）受体拮抗剂SCH 23390或D2 DA受体拮抗剂L-舒必利阻断。黑质纹状体DA能通路的病变废除LTD。DA耗竭后，LTD可以恢复的应用外源性DA。LTD也可以恢复由共同管理的D1和D2 DA受体激动剂，但不是由单独应用一类DA受体激动剂。我们的数据表明，共激活D1和D2 DA受体所需的LTD在纹状体。D1/D2受体在LTD诱导中的协同作用可能在DA的行为功能和DA激动剂在帕金森病中的治疗作用中起关键作用。
Long-term changes of synaptic transmission following brief trains of high-frequency stimulation of excitatory pathways in the brain have attracted attention as a possible correlate of memory. In the cerebellum, concurrent activation of parallel fibers and climbing fibers leads to a long-term depression (LTD) of synaptic transmission, which may be the cellular substrate of motor learning in this structure. We report here for the first time that high-frequency stimulation of corticostriatal glutamatergic fibers in the striatum, another brain structure strongly involved in motor control, also induces LTD of synaptic transmission. Induction of striatal LTD is blocked either by SCH 23390, a D1 dopamine (DA) receptor antagonist or by L-sulpiride, a D2 DA receptor antagonist. The lesion of the nigrostriatal DAergic pathway abolishes LTD. After DA depletion, LTD can be restored by the application of exogenous DA. LTD can also be restored by coadministration of D1 and D2 DA receptor agonists, but not by the application of a single class of DA agonists alone. Our data show that coactivation of D1 and D2 DA receptors is required for LTD in the striatum. D1/D2 receptor cooperation in the induction of LTD may play a crucial role in the behavioural function of DA and in the therapeutic effects of DA agonists in Parkinson's disease.